
ALUMIS INC.
100
Recent developments for ALUMIS INC. focus on clinical trial progress for Envudeucitinib, insider buying activity, and financial transactions including a public offering.
- ALUMIS INC. reported positive Phase 3 data for Envudeucitinib in plaque psoriasis, with the drug delivering the highest PASI 100 skin clearance rates, leading to stock price increases in early October 2026 [N2][N3].
- The company’s lupus trial missed primary endpoints but showed promise in a high-interferon subgroup, indicating potential for targeted patient populations [N5].
- Insider buying was reported in September 2026, suggesting confidence from company insiders in the business outlook [N4].
- ALMS completed an upsized public offering with full exercise of underwriters’ option to purchase additional shares in January 2026, supporting its capital base [N3].
- Multiple analyst buy recommendations and coverage initiations were reported in early 2026, reflecting positive market interest [N2].
ALUMIS INC. is a clinical-stage biopharmaceutical company specializing in treatments for dermatological and autoimmune conditions. Its lead drug candidate, Envudeucitinib, targets plaque psoriasis and has demonstrated strong efficacy in Phase 3 trials, including the highest PASI 100 skin clearance rates reported. The company also conducted a lupus trial that did not meet primary endpoints but indicated potential benefits in a specific patient subgroup. ALMS maintains collaborative arrangements for product development and licensing, including with Kaken Pharmaceutical Co. Ltd. The company has engaged in capital raising activities, including an upsized public offering in early 2026. Financially, ALMS reported a net loss in the third quarter of 2026 but holds substantial cash and short-term investments, supporting ongoing operations.
Financial figures (if any) are summarized from the latest available SEC filings and are provided for informational purposes only — not financial advice. ALUMIS INC. is a biopharmaceutical company focused on dermatology and autoimmune diseases, notably developing Envudeucitinib for plaque psoriasis. The company reported positive Phase 3 clinical trial data for Envudeucitinib in October 2026, with the drug delivering the highest PASI 100 skin clearance in plaque psoriasis. A lupus trial missed main goals but showed promise in a high-interferon subgroup. Insider buying activity and an upsized public offering were reported in early 2026. As of September 30, 2026, ALMS had strong liquidity with $57.7 million in cash and $218.8 million in short-term investments, but reported a net loss of $94.9 million for the quarter.
Positive Phase 3 clinical trial results for Envudeucitinib in plaque psoriasis demonstrate strong efficacy, positioning ALMS as a competitive player in dermatology therapeutics. Insider buying activity and analyst buy recommendations reflect confidence in the company's pipeline and strategic direction. The company's strong liquidity position supports continued clinical development and operational activities. Collaborative arrangements may facilitate broader development and commercialization opportunities.
The lupus trial missed its primary endpoints, indicating challenges in expanding the drug's indications beyond psoriasis. The company reported a significant net loss in the latest quarter, reflecting ongoing high expenses typical of clinical-stage biopharmaceutical firms. Regulatory and clinical risks remain inherent, with future approvals and market acceptance uncertain. Dependence on a limited number of drug candidates and collaborations may expose ALMS to concentration risks.
ALUMIS INC.'s moat is primarily based on its proprietary drug candidate Envudeucitinib, which has shown superior clinical efficacy in plaque psoriasis treatment compared to competitors, as evidenced by the highest PASI 100 skin clearance rates in Phase 3 trials. The company's collaborations and licensing agreements, such as with Kaken Pharmaceutical Co. Ltd., provide strategic partnerships that may enhance development and commercialization capabilities. However, as a clinical-stage biopharmaceutical company, its moat is contingent on successful regulatory approvals and market adoption of its drug candidates.
• Clinical Trial Risk: The success of ALMS depends on positive clinical trial outcomes and regulatory approvals. The lupus trial missed main goals, highlighting the risk of unsuccessful trials impacting pipeline value.
• Financial Risk: ALMS reported a net loss of $94.9 million for Q3 2026, indicating ongoing high expenses and the need for sufficient capital to fund operations.
• Regulatory Risk: Approval of drug candidates by regulatory authorities is uncertain and may delay or prevent commercialization.
• Market Adoption Risk: Even with regulatory approval, market acceptance of Envudeucitinib depends on competitive positioning and physician/patient adoption.
Business trends: ALMS is advancing its lead drug Envudeucitinib with positive Phase 3 psoriasis data and exploring targeted lupus patient subgroups.
Execution milestones: Completion of Phase 3 trials, public offering capital raises, and ongoing regulatory submissions.
Key risks: Clinical trial uncertainties, regulatory approval challenges, financial sustainability, and market adoption risks.
Very high visibility
Visibility score reflects the breadth and consistency of available disclosure across SEC filings, recent public reporting, and baseline business context (research-only; not investment advice).
- ALUMIS INC. is a biopharmaceutical company focused on developing treatments for dermatological and autoimmune diseases.
- The company is developing Envudeucitinib, a drug candidate for plaque psoriasis, which has reported positive Phase 3 clinical trial data.
- Envudeucitinib delivered the highest PASI 100 skin clearance in plaque psoriasis trials, indicating strong efficacy.
- ALMS reported positive Phase 3 data for Envudeucitinib in October 2026, with stock price increases following the announcements.
- The company conducted a lupus trial which missed main goals but showed promise in a high-interferon subgroup.
- Insider buying activity was reported in September 2026, indicating confidence from company insiders.
- ALMS has completed an upsized public offering with full exercise of underwriters’ option to purchase additional shares in January 2026.
- The company’s financial snapshot as of September 30, 2026, shows cash and equivalents of $57.7 million and short-term investments of $218.8 million, with a current ratio of 5.57 and cash ratio of 3.48, indicating strong liquidity.
- Net income for the quarter ended September 30, 2026, was a loss of $94.9 million, with basic and diluted EPS of -$0.73 per share.
- ALMS operates under a collaborative arrangement with Kaken Pharmaceutical Co. Ltd. for product development and licensing.
- The company’s recent news coverage includes multiple reports on clinical trial progress, insider transactions, and analyst coverage with buy recommendations.
Generated 2026-11-15
- S1 | 2026-03-19 | 10-K
- S2 | 2026-11-12 | 10-Q
- N1 | 2026-11-05 | www.nasdaq.com | Iovance Biotherapeutics (IOVA) Reports Q3 Loss, Beats Revenue Estimates | https://www.nasdaq.com/articles/iovance-biotherapeutics-iova-reports-q3-loss-beats-revenue-estimates
- N2 | 2026-10-09 | www.nasdaq.com | Alumis Reports Positive Phase 3 Data With Envudeucitinib | https://www.nasdaq.com/articles/alumis-reports-positive-phase-3-data-envudeucitinib
- N3 | 2026-10-09 | www.nasdaq.com | Alumis Shares New Phase 3 Psoriasis Data For Envudeucitinib; Stock Up | https://www.nasdaq.com/articles/alumis-shares-new-phase-3-psoriasis-data-envudeucitinib-stock
- N4 | 2026-09-10 | www.nasdaq.com | Thursday 9/10 Insider Buying Report: ALMS, PRTS | https://www.nasdaq.com/articles/thursday-9-10-insider-buying-report-alms-prts
- N5 | 2026-09-01 | www.nasdaq.com | Alumis Lupus Trial Misses Main Goals, but High-Interferon Subgroup Shows Promise | https://www.nasdaq.com/articles/alumis-lupus-trial-misses-main-goals-high-interferon-subgroup-shows-promise
- N6 | 2026-08-11 | www.nasdaq.com | 4 Psoriasis Drug Stocks to Watch During Psoriasis Awareness Month 2026 | https://www.nasdaq.com/articles/4-psoriasis-drug-stocks-watch-during-psoriasis-awareness-month-2026
- N7 | 2026-08-11 | www.nasdaq.com | Alumis: Envudeucitinib Delivered Highest PASI 100 Skin Clearance In Plaque Psoriasis | https://www.nasdaq.com/articles/alumis-envudeucitinib-delivered-highest-pasi-100-skin-clearance-plaque-psoriasis
- N8 | 2026-08-06 | www.nasdaq.com | Prothena (PRTA) Reports Q2 Loss, Misses Revenue Estimates | https://www.nasdaq.com/articles/prothena-prta-reports-q2-loss-misses-revenue-estimates
This material is for informational purposes only and does not constitute investment, financial, legal or tax advice, or an offer or solicitation to buy or sell any security. The Valye AI Score is a model-based estimate derived from public information and is subject to change without notice. No representation or warranty, express or implied, is made as to the accuracy, completeness or fairness of the information herein. Past performance is not indicative of future results. Investors should conduct their own research and consult a qualified financial adviser before making any investment decisions.

Generated by Valye SEC Pipeline Engine
.gif)


